Nested Therapeutics

Biotech · Private

Small molecule RAS and ERK pathway inhibitors for KRAS-mutant cancers

nestedtx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
28
0 granted · 28 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3061Parabolica Therapeutics, Inc.—$50K
3062Centessa Pharmaceuticals——
3063Entrega——
3064Nested Therapeutics——
3065ELSOHLY LABORATORIES, INC.——
3066490 BIOTECH INC——
3067Synthis Therapeutics, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 28
  • Mitogen-activated Protein Kinase (mek) Inhibitorsapplication
  • Heterocyclic Derivatives As Mitogen-activated Protein Kinase (mek) Inhibitorsapplication
  • Mitogen-activated Protein Kinase (mek) Inhibitorsapplication
  • P53 Modulatorsapplication
  • P53 Modulatorsapplication
  • Inhibitors Of Akt And Uses Thereofapplication
  • Crystalline Forms Of 3-[[3-FLUORO-2-(METHYLSULFAMOYLAMINO)-4-PYRIDYL]METHYL]-7-[(3-FLUORO-2-PYRIDYL)OXY]-4-METHYL-CHROMEN-2-ONEapplication
  • P53 Modulatorsapplication
  • Mitogen-activated Protein Kinase (mek) Inhibitorsapplication
  • P53 Modulatorsapplication
  • P53 Modulatorsapplication
  • P53 Modulatorsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.